Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Thursday, September 24, 2026

⚡ Executive Takeaway

The panel said yes to the device and hedged on the word in its name. That is the grade on the scenario we published yesterday: we said the unpriced outcome was an approvable device with a narrowed claim, made scientifically respectable by the FDA's own timing bias caveat. The effectiveness question, the one that decides whether "early detection" survives into the label, was the only vote that nearly split. Four panelists looked at the same stage tables the agency printed and declined to call the test effective; six accepted the screening gap framing instead. Both camps now feed the FDA's label negotiation, and the negotiation is the asset. Meanwhile the market never got a say. A halt is an unusual gift in a week like this: it forces a full night of distance between the evidence and the price. Thursday's open settles whether a prepaid rally survives contact with a narrow margin on the one question that funds the revenue model. Watch the open, then watch what language Grail asks for.

The count, the debate, and the field it reshapes, all below. 👉 Read Full Analysis

🔬 Diagnostics

The panel gave Grail every vote and left the label fight alive. GRAL

The Molecular and Clinical Genetics Devices Panel found reasonable assurance on all three questions, per Grail's release: safety 10 to 0, effectiveness 6 to 4, benefit risk 7 to 2 with one abstention. Per meeting coverage, FDA staff pressed whether the data support calling Galleri an "early detection" test at all, with stage I to II sensitivity of 24.9% and 20.5% in the two pivotal studies, while supporters leaned on the screening gap the agency's own summary printed: 47.3% sensitivity where no screening exists versus 22.9% where guidelines already screen. The FDA decides the first MCED PMA in the coming months. Grail called the tally a reinforcement of its evidence; the four no votes on effectiveness are the part the label negotiation will remember.

🩺 Kidney Disease

One readout redrew the IgA nephropathy map, and the incumbents paid for it on the tape. RHHBY | IONS | VERA

Roche's sefaxersen, the antisense factor B medicine licensed from Ionis, met the primary endpoint of its Phase 3 Imagination study at the week 37 interim with a statistically significant proteinuria reduction, per Fierce Biotech; the trial stays blinded to week 105 for kidney function and Roche will push for accelerated approval. That puts a second complement factor B agent on the board next to Novartis's oral Fabhalta, dosed monthly by injection instead of twice daily by mouth. The session's tape treated it as a share fight: VERA fell 8.9% to 33.05 and IONS fell 4.0% despite being the drug's discoverer; neither company disclosed anything and we assign no cause. Vertex's povetacicept decision lands November 30 in the same disease.

💉 Obesity and Metabolic

Novo floated a New York listing while Lilly claimed 7 of 10 Medicare starts. NVO | LLY

Chief executive Mike Doustdar told the Financial Times that Novo is "open to the idea" of a direct NYSE listing to replace its ADR structure, while not actively pursuing one, per Fierce Pharma; the US is now more than half of revenue. The ADRs fell another 3.1% to 38.17, a third straight decline since the capital markets day, with EASD opening Monday in Milan as the next dated test. On the other side of the class, David Ricks told CNBC that Lilly captures about 70% of Medicare GLP-1 bridge starts and that Foundayo takes roughly one in three new oral starts; Jefferies pegs the bridge share at about $1.4 billion annualized. Every number in that paragraph is a statement, not a filing, and we treat them accordingly.

🧪 Immunology

Immunovant folded a lupus program on the spot rather than argue with its own data. IMVT

IMVT-1402 missed the primary endpoint of a 57 patient Phase 2 in cutaneous lupus erythematosus, with week 12 skin scores statistically no better than placebo, per Fierce Biotech. The company cited "the competitive landscape and the clinical results observed," noted that deeper IgG reductions tracked with response, and moved on; the anti FcRn antibody continues in Graves' disease, rheumatoid arthritis, myasthenia gravis, CIDP, and Sjögren's. IMVT closed at 34.54, down 7.4%. A same day discontinuation on a clean miss is what capital discipline looks like in this market, and the stock's modest penalty suggests investors agree.

🩻 Medtech and Policy

CMS priced the lab industry's next three years, and Cordis broke a coated balloon monopoly. BSX

CMS's preliminary 2027 Clinical Laboratory Fee Schedule would cut payment on nearly 1,200 tests, 775 of them at the 15% annual cap set by PAMA, with more reductions queued for 2028 and 2029; the agency says Medicare pays about 16% above private rates, per MedTech Dive (September 22). Final rates land in November, an awkward backdrop for every diagnostic awaiting an FDA decision, Galleri included. Cordis meanwhile won FDA approval for Selution SLR, a sirolimus eluting balloon for coronary in stent restenosis and the first US alternative to Boston Scientific's Agent, per MedTech Dive (September 22). And Oura set terms for a Nasdaq IPO of up to $2.2 billion at $40 to $44 a share, mostly from selling stockholders, per MedTech Dive (September 21).

📉 The Tape

The red column grew again, and most of it came without news. XENE | BHVN | CLDX | ETRA

XENE fell 6.5% to 36.56 and BHVN gave back 7.9% to 13.67, unwinding two unexplained up sessions; no news found for either, scope tonight's sweep. CLDX slid another 7.1% to 31.12, now down 17.9% from Monday with the double Phase 3 win still unexplained by any disclosure. ETRA slipped 7.0% to 12.67, now 15.5% below its $15.00 offer with the greenshoe clock running toward late October. TLX fell 5.7% to 11.27, back below the $11.841 ITM strike one day after reclaiming it. SRRK eased 2.6% and RARE fell 4.7%, both still without pricing documents for their new approvals; Scrip has reported Isembyld above $450,000 a year list with a net near $310,000, the only price sighting so far and Scrip's alone. All closes are exchange settled; percentages our arithmetic.

📋 Quick Hits

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →

The gauntlet's second event delivered on schedule, and for once the market had to sleep on the answer. Tomorrow CERVINO's withheld medians come due, and Friday's edition grades the whole week. What are you watching? Reply to this email.

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →